We are live on ! Find out more
NMRA icon

Neumora Therapeutics
NMRA

60 hedge funds and large institutions have $745M invested in Neumora Therapeutics in 2023 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 9 increasing their positions, 8 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

183% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 12

61% more call options, than puts

Call options by funds: $359K | Put options by funds: $223K

58% more funds holding

Funds holding: 38 → 60 (+22)

46% more capital invested

Capital invested by funds: $512M → $745M (+$233M)

13% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 8

4.83% more ownership

Funds ownership: 23.84% → 28.67% (+4.8%)

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

Holders
60
Holders Change
+22
Holders Change %
+57.89%
% of All Funds
0.87%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.04%
New
34
Increased
9
Reduced
8
Closed
12
Calls
$359K
Puts
$223K
Net Calls
+$136K
Net Calls Change
+$136K

Top Buyers

Rank Fund Capital Flow
1
IC
Iconiq Capital
California
+$41.7M
2
BlackRock
BlackRock
New York
+$12.5M
3
JJ
Johnson & Johnson
New Jersey
+$11.5M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$9.19M
5
Goldman Sachs
Goldman Sachs
New York
+$6.37M

Top Sellers

Rank Fund Capital Flow
1
SCM
Soros Capital Management
New York
-$8.3M
2
Citadel Advisors
Citadel Advisors
Florida
-$3.99M
3
Millennium Management
Millennium Management
New York
-$3.88M
4
Marshall Wace
Marshall Wace
United Kingdom
-$3.62M
5
AG
Artal Group
Luxembourg
-$3.07M
Name Holding Trade Value Shares
Change 		Change in
Stake
SO
51
STRS Ohio
Ohio
$54K +$39.3K +3,200 New
TRCT
52
Tower Research Capital (TRC)
New York
$43.6K +$31.4K +2,558 New
California State Teachers Retirement System (CalSTRS)
53
California State Teachers Retirement System (CalSTRS)
California
$41.8K +$30.1K +2,449 New
AB
54
Amalgamated Bank
New York
$29K +$21K +1,709 New
AIP
55
Ameritas Investment Partners
Nebraska
$26.3K +$18.9K +1,540 New
Legal & General Group
56
Legal & General Group
United Kingdom
$24.2K -$105K -8,578 -86%
MLICM
57
Metropolitan Life Insurance Company (MetLife)
New York
$15.7K +$11.3K +921 New
UBS Group
58
UBS Group
Switzerland
$4.37K +$3.14K +256 New
ASN
59
Advisory Services Network
Georgia
$3.41K +$2.46K +200 New
QL
60
Quarry LP
New York
$853 +$614 +50 New
SCM
61
Soros Capital Management
New York
– -$8.3M -588,235 Closed
Millennium Management
62
Millennium Management
New York
– -$3.88M -274,748 Closed
Marshall Wace
63
Marshall Wace
United Kingdom
– -$3.62M -256,412 Closed
Two Sigma Investments
64
Two Sigma Investments
New York
– -$825K -58,500 Closed
GCM
65
Greenland Capital Management
New York
– -$672K -47,613 Closed
PMEF
66
Point72 Middle East FZE
United Arab Emirates
– -$617K -43,713 Closed
First Trust Advisors
67
First Trust Advisors
Illinois
– -$378K -26,770 Closed
LCM
68
Laurion Capital Management
New York
– -$304K -21,557 Closed
Qube Research & Technologies (QRT)
69
Qube Research & Technologies (QRT)
United Kingdom
– -$302K -21,400 Closed
ZP
70
Zimmer Partners
New York
– -$176K -12,500 Closed
SFM
71
Soros Fund Management
New York
– -$141K -10,000 Closed
SIC
72
Salem Investment Counselors
North Carolina
– -$1.41K -100 Closed
1 2
3

NMRA Hedge Fund Activity: Q4 2023 in Review

60 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Neumora Therapeutics (NMRA) for Q4 2023, worth a combined $745M — up 46% from $512M a quarter earlier.

Buyers outnumbered sellers: 34 funds opened new NMRA positions and 12 closed out — a net gain of 22 holders — while 9 added to existing stakes and 8 trimmed.

The largest buyer was Iconiq Capital, opening a new position worth an estimated $41.7M. The largest seller was Soros Capital Management, exiting entirely with an estimated $8.3M sold.

  • 60 institutional investors held Neumora Therapeutics (NMRA) as of Q4 2023, up from 38 in Q3 2023.
  • Funds reported $745M of Neumora Therapeutics stock for Q4 2023, up 46% quarter-over-quarter.
  • 34 funds opened new Neumora Therapeutics positions in Q4 2023 and 12 closed out, a net change of +22 holders.
  • The largest Neumora Therapeutics buyer in Q4 2023 was Iconiq Capital, an estimated $41.7M added.
  • The largest Neumora Therapeutics seller in Q4 2023 was Soros Capital Management, an estimated $8.3M sold.

Based on aggregated 13F filings for Q4 2023.